Section: Avian Bacteria

Avian Influenza Vaccine: Types, Strategies, and Efficacy in Poultry

Introduction

Avian influenza virus (AIV) is an enveloped, negative-sense, single-stranded RNA virus belonging to the family Orthomyxoviridae. The virus is classified into low pathogenicity avian influenza (LPAI) and highly pathogenic avian influenza (HPAI) based on its virulence in chickens. Control of AIV in poultry relies on a combination of biosecurity, surveillance, stamping-out policies, and vaccination. The use of an avian influenza vaccine is a critical tool in endemic regions and during outbreak responses, as it can reduce clinical signs, viral shedding, and transmission. This article provides a detailed review of the types of avian influenza vaccines, vaccination strategies, efficacy parameters, and differentiation of infected from vaccinated animals (DIVA) approaches.

Avian Influenza Virus Biology and Vaccine Targets

AIV is characterized by two surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA). The HA protein mediates viral attachment to sialic acid receptors on host cells and is the primary target of neutralizing antibodies. The NA protein facilitates viral release from infected cells. The internal proteins, including the nucleoprotein (NP) and matrix protein (M1), are more conserved and serve as targets for some diagnostic assays and cross-reactive immune responses. The high mutation rate of the viral RNA-dependent RNA polymerase, combined with segment reassortment, drives antigenic drift and shift, necessitating periodic vaccine strain updates. The World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) provide guidance on vaccine strain selection to match circulating field strains.

Types of Avian Influenza Vaccines

Several vaccine platforms have been developed for AIV in poultry, each with distinct immunological and practical characteristics.

Inactivated Whole Virus Vaccines

Inactivated whole virus (IWV) vaccines are the most widely used type of avian influenza vaccine in poultry. These vaccines are produced by propagating AIV in embryonated chicken eggs, chemically inactivating the virus (typically with formalin or beta-propiolactone), and emulsifying the antigen with an oil adjuvant. The oil adjuvant enhances the immunogenicity of the inactivated antigen, promoting a strong humoral immune response. IWV vaccines are typically administered via subcutaneous or intramuscular injection. They induce antibodies primarily against the HA and NA proteins, providing subtype-specific protection. A major advantage of IWV vaccines is their safety profile, as they contain no live virus. However, they require individual bird handling for administration, which is labor-intensive and costly for large flocks. Furthermore, IWV vaccines do not induce robust mucosal immunity, which may limit their ability to prevent infection at the respiratory and intestinal portals of entry.

Recombinant Vectored Vaccines

Recombinant vectored vaccines use a live, non-pathogenic virus or bacterium as a vector to deliver and express AIV immunogens, most commonly the HA gene. The most widely used vectors in poultry include fowl poxvirus (FPV) and herpesvirus of turkeys (HVT). The FPV-vectored H5 vaccine (rFPV-H5) and HVT-vectored H5 vaccine (rHVT-H5) are commercially available. These vaccines can be administered in ovo (into the embryonated egg) or subcutaneously at day of age. The vector replicates in the host, leading to endogenous expression of the HA protein and stimulation of both humoral and cell-mediated immune responses. A key advantage of vectored vaccines is their ability to be administered at a large scale, including in ovo vaccination, which reduces labor costs. They also allow for DIVA strategies, as vaccinated birds will not develop antibodies to the internal proteins of AIV (e.g., NP). However, pre-existing immunity to the vector (e.g., maternal antibodies against HVT) can interfere with vaccine efficacy.

DNA Vaccines

DNA vaccines consist of a plasmid encoding the AIV HA gene under the control of a strong eukaryotic promoter. After intramuscular or intradermal injection, the plasmid is taken up by host cells, and the HA protein is expressed endogenously, leading to both humoral and cellular immune responses. DNA vaccines offer advantages in terms of rapid production, stability, and the absence of live virus. However, their immunogenicity in poultry has been variable, often requiring multiple doses or the use of adjuvants or electroporation to achieve protective immunity. DNA vaccines are not yet widely used in commercial poultry production but remain an area of active research.

Other Experimental Platforms

Other vaccine platforms under investigation include virus-like particles (VLPs), which are self-assembling, non-infectious structures that display HA and NA on their surface, and live attenuated influenza vaccines (LAIV), which are generated through reverse genetics to produce a temperature-sensitive or replication-restricted virus. LAIVs can induce strong mucosal immunity but carry a risk of reassortment with field strains. Subunit vaccines, which use purified HA or NA proteins produced in baculovirus or other expression systems, are also being explored.

Vaccination Strategies

The choice of vaccination strategy depends on the epidemiological context, production system, and regulatory framework.

Emergency Vaccination

During an HPAI outbreak, emergency vaccination may be implemented as a supplement to stamping-out measures. The goal is to reduce the number of susceptible birds, decrease viral shedding, and slow the spread of the virus. Emergency vaccination typically uses IWV vaccines matched to the circulating strain. Vaccination zones are established around infected premises, and birds in these zones are vaccinated. This strategy requires rapid vaccine production and distribution.

Routine Endemic Vaccination

In regions where LPAI or HPAI is endemic, routine vaccination is used to maintain flock immunity and prevent clinical disease. Vaccination schedules vary but often involve a prime-boost regimen. For example, broiler breeders may receive a primary vaccination with an IWV vaccine at 6-8 weeks of age, followed by a booster at 16-18 weeks of age. Layers may be vaccinated every 3-6 months to maintain antibody titers. In broilers, a single vaccination at day of age with a vectored vaccine (e.g., rHVT-H5) is common.

Mass Vaccination via Drinking Water or Spray

While most AIV vaccines are administered parenterally, research has explored mass vaccination methods such as drinking water or spray application. These methods are less stressful for birds and require less labor. However, they are generally less effective for IWV vaccines, which require an oil adjuvant. Some live vectored vaccines can be administered via drinking water, but the efficacy of this route for AIV vaccines remains under investigation.

Efficacy of Avian Influenza Vaccines

Vaccine efficacy is assessed by measuring the reduction in clinical signs, mortality, viral shedding, and transmission. Standardized challenge studies are used to evaluate vaccine performance. The WOAH Terrestrial Manual provides guidelines for vaccine efficacy testing.

Humoral Immune Response

The primary correlate of protection for IWV vaccines is the hemagglutination inhibition (HI) antibody titer. An HI titer of 1:16 or higher is generally considered protective against homologous challenge. However, the HI titer required for protection against heterologous strains may be higher. Vaccinated birds with high HI titers show reduced oropharyngeal and cloacal viral shedding, which decreases environmental contamination and transmission.

Reduction in Viral Shedding

A key goal of vaccination is to reduce viral shedding to levels that prevent onward transmission. Studies have shown that IWV vaccines can reduce the amount of virus shed from the respiratory and gastrointestinal tracts by several orders of magnitude. However, vaccinated birds can still become infected and shed low levels of virus, particularly if the vaccine strain is antigenically mismatched to the challenge strain. This phenomenon, known as "silent spread," is a major concern for HPAI control, as it can allow the virus to circulate undetected.

Duration of Immunity

The duration of immunity varies by vaccine type and bird age. IWV vaccines typically provide protective HI titers for 4-6 months after a single dose, with boosters extending this period. Vectored vaccines, such as rHVT-H5, can provide protection for the lifespan of a broiler (6-8 weeks) with a single in ovo or day-old dose. In long-lived birds like layers and breeders, regular boosters are necessary.

Antigenic Drift and Vaccine Mismatch

The continuous evolution of AIV through antigenic drift can lead to vaccine mismatch, where the vaccine strain is no longer antigenically similar to circulating field strains. This reduces vaccine efficacy and can lead to breakthrough infections. Surveillance programs that monitor the genetic and antigenic characteristics of field strains are essential for updating vaccine strains. The WHO, WOAH, and FAO coordinate a global network of laboratories for this purpose.

DIVA Strategies

Differentiating infected from vaccinated animals (DIVA) is a critical component of vaccination programs, as it allows for serological surveillance to detect field virus circulation in vaccinated flocks. Several DIVA strategies have been developed.

Sentinel Birds

The simplest DIVA strategy involves placing unvaccinated sentinel birds in vaccinated flocks. These sentinels are monitored for seroconversion to AIV, which indicates field virus exposure. This approach is straightforward but requires additional bird management and does not allow for high-throughput testing.

Heterologous NA Vaccines

This strategy uses a vaccine containing an NA subtype different from the circulating field strain. For example, an H5N1 vaccine (with N1 NA) can be used in an area where an H5N2 field virus (with N2 NA) is circulating. Vaccinated birds will develop antibodies to N1, while infected birds will develop antibodies to N2. Serological tests specific for the N2 NA can then differentiate infected from vaccinated birds. This approach requires careful matching of vaccine and field NA subtypes.

Serological DIVA Using Internal Protein Antibodies

IWV vaccines contain whole inactivated virus, including internal proteins like NP and M1. Vaccinated birds will therefore develop antibodies to these proteins. To enable DIVA, vaccines can be produced using purified HA and NA antigens (subunit or recombinant vaccines) that lack internal proteins. Serological tests, such as the commercial ELISA kits targeting the NP protein, can then detect antibodies to NP only in infected birds. This is the basis for many DIVA programs using vectored or subunit vaccines.

Molecular DIVA

Molecular DIVA strategies use real-time reverse transcription polymerase chain reaction (RT-PCR) assays that target specific genetic markers present in field strains but absent in vaccine strains. For example, a vaccine strain may have a deletion in the NA gene or a specific mutation in the HA cleavage site that distinguishes it from wild-type virus. This approach requires detailed genetic characterization of both vaccine and field strains.

Integration with Other Control Measures

Vaccination is not a standalone solution for AIV control. It must be integrated with robust biosecurity measures, including quarantine, disinfection, and movement restrictions. Surveillance using molecular detection methods, such as RT-PCR and sequencing, is essential for early detection of field virus incursions. The use of an avian influenza vaccine should be part of a comprehensive control program that includes education of producers, rapid response protocols, and collaboration with veterinary authorities. For a detailed discussion of transmission pathways and biosecurity, refer to the article on Avian Influenza (HPAI) Spread: Transmission Pathways, Biosecurity, and Clinical Implications.

Challenges and Future Directions

Several challenges remain for AIV vaccination in poultry. The high cost of vaccine production and administration, particularly for IWV vaccines, can be prohibitive in resource-limited settings. The need for frequent vaccine strain updates due to antigenic drift requires a robust surveillance and vaccine manufacturing infrastructure. Additionally, the potential for vaccine-induced selection pressure to drive viral evolution is a theoretical concern. Future directions include the development of broadly protective vaccines targeting conserved epitopes, such as the HA stalk domain or the M2e protein. Advances in reverse genetics and synthetic biology may enable the rapid production of custom-designed vaccines. The use of computational biology and structural prediction tools, as discussed in Structural Prediction of Viral Envelope Glycoproteins Using AlphaFold2: Implications for Host Receptor Binding and Vaccine Design, may aid in the rational design of next-generation vaccines.

Conclusion

The avian influenza vaccine is an essential tool for the control of AIV in poultry. Inactivated whole virus vaccines remain the most widely used platform, while recombinant vectored vaccines offer advantages for mass vaccination and DIVA compatibility. DNA vaccines and other experimental platforms are under development. Vaccination strategies must be tailored to the epidemiological context and integrated with biosecurity and surveillance. Efficacy is measured by the reduction in clinical signs, viral shedding, and transmission, and is influenced by antigenic match and vaccine type. DIVA strategies, including sentinel birds, heterologous NA vaccines, and serological or molecular assays, are critical for maintaining surveillance in vaccinated populations. Continued research and international collaboration are needed to address the challenges of antigenic drift, cost, and vaccine delivery.

References

  1. Swayne, D. E., & Kapczynski, D. R. (2008). Strategies and challenges for eliciting immunity against avian influenza virus in birds. Immunological Reviews, 225(1), 314-331.
  2. Suarez, D. L., & Schultz-Cherry, S. (2000). Immunology of avian influenza virus: a review. Developmental & Comparative Immunology, 24(2-3), 269-283.
  3. Capua, I., & Marangon, S. (2006). Control of avian influenza in poultry. Emerging Infectious Diseases, 12(9), 1319-1324.
  4. Swayne, D. E. (2012). Impact of vaccine-induced immunity on the epidemiology of avian influenza. Avian Diseases, 56(4s1), 818-828.
  5. van den Berg, T., Lambrecht, B., Marche, S., Steensels, M., & Van Borm, S. (2008). Influenza vaccines and vaccination strategies in birds. Comparative Immunology, Microbiology and Infectious Diseases, 31(2-3), 121-165.
  6. Bublot, M., Pritchard, N., Swayne, D. E., Selleck, P., Karaca, K., Suarez, D. L., ... & Mickle, T. R. (2006). Development and use of fowlpox vectored vaccines for avian influenza. Annals of the New York Academy of Sciences, 1081(1), 193-201.
  7. Rauw, F., Palya, V., Van Borm, S., Welby, S., Tatar-Kis, T., Gardin, Y., ... & Lambrecht, B. (2011). Further evidence of the efficacy of a turkey herpesvirus-vectored avian influenza H5 vaccine against challenge with a clade 2.2.1 H5N1 highly pathogenic avian influenza virus in chickens. Avian Pathology, 40(5), 477-484.
  8. Maas, R., Tacken, M., Ruuls, L., Koch, G., & van Rooij, E. (2009). Avian influenza (H5N1) vaccination of chickens: a comparison of humoral and cellular immune responses against different vaccine types. Vaccine, 27(42), 5800-5806.
  9. Suarez, D. L. (2005). Overview of avian influenza DIVA test strategies. Biologicals, 33(4), 221-226.
  10. Swayne, D. E., & Suarez, D. L. (2000). Highly pathogenic avian influenza. Revue Scientifique et Technique (International Office of Epizootics), 19(2), 463-482.
  11. World Organisation for Animal Health (WOAH). (2021). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Chapter 3.3.4: Avian Influenza (including infection with high pathogenicity avian influenza viruses).
  12. Spackman, E., & Swayne, D. E. (2013). Vaccination of gallinaceous poultry for H5N1 highly pathogenic avian influenza: current questions and new technologies. Veterinary Microbiology, 165(1-2), 1-7.
  13. Lee, C. W., & Suarez, D. L. (2005). Avian influenza virus: prospects for prevention and control by vaccination. Vaccine, 23(50), 5749-5755.
  14. Capua, I., & Alexander, D. J. (2004). Avian influenza: recent developments. Avian Pathology, 33(4), 393-404.
  15. Swayne, D. E., & Pantin-Jackwood, M. (2006). Pathogenicity of avian influenza viruses in poultry. Developments in Biologicals, 124, 61-67.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.